Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: A comparison with 2.5-mg once-daily dosage regimen

Journal of Bone and Mineral Metabolism

Volumn 24, Issue 5, 2006, Pages 405-413

  Kishimoto, Hideaki ^a   Fukunaga, Masao ^b   Kushida, Kazuhiro ^c   Shiraki, Masataka ^d   Itabashi, Akira ^e   Nawata, Hajime ^f   Nakamura, Toshitaka ^g   Ohta, Hiroaki ^h   Takaoka, Kunio ⁱ   Ohashi, Yasuo ^j  

^a SAN IN ROSAI HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Bisphosphonate; Bone mineral density; Once weekly regimen; Osteoporosis; Risedronate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; GAMMA GLUTAMYLTRANSFERASE; RISEDRONIC ACID;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE DENSITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; INVOLUTIONAL OSTEOPOROSIS; JAPAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; OSSIFICATION; OSTEOLYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMACH DISCOMFORT;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 33748101881     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-006-0706-z     Document Type: Article

References (27)

1. ST Harris NB Watts HK Genant CD [tmp] McKeever T Hangartner M Keller CH Chesnut III J Brown E Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1344 1352
2. J-Y Reginster OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 83 89
3. MR [tmp] McClung P Geusens PD Miller H Zippel WG Bensen C Roux S Adami I Fogelman T Diamond R Eastell PJ Meunier J-Y Reginster 2001 Effect of risedronate on the risk of hip fracture in elderly women N Engl J Med 344 333 340
4. I Fogelman C Ribot R Smith D Ethgen E Sod J-Y Reginster 2000 Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial J Clin Endocrinol Metab 85 1895 1900
5. OH Sorensen GM Crawford H Mulder DJ Hosking C Gennari D Mellstrom S Pack D Wenderoth C Cooper J-Y Reginster 2003 Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience Bone 32 120 126
6. DD Mellstrom OH Sorensen S Goemaere C Roux TD Johmson AA Chines 2004 Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcif Tissue Int 75 462 468
7. M Fukunaga K Kushida H Kishimoto M Shiraki Y Taketani H Minaguchi T Inoue R Morita H Morii K Yamamoto Y Ohashi H Orimo 2002 A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial Osteoporos Int 13 971 979
8. K Kushida M Fukunaga H Kishimoto M Shiraki A Itabashi T Inoue K Kaneda H Morii H Nawata K Yamamoto Y Ohashi H Orimo 2004 A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial J Bone Miner Metab 22 470 479
9. Y Ogura A Gonsho Orimo H Cyong J-C 2004 Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies J Bone Miner Metab 22 111 119
10. DY Mitchell RA Eusebio NA Sacco-Gibson KA Pallone SC Kelly JD Nesbitt CP Brezovic GA Thompson JH Powell 2000 Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers J Clin Pharmacol 40 258 265
11. M Shiraki M Fukunaga K Kushida H Kishimoto Y Taketani H Minaguchi T Inoue R Morita H Morii K Yamamoto Y Ohashi H Orimo 2003 A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group) Osteoporos Int 14 225 234
12. JH Lin 1996 Bisphosphonates: a review of their pharmacokinetic properties Bone 18 75 85
13. JG Seedor HA Quartuccio DD Thompson 1991 The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats J Bone Miner Res 6 339 346
14. F Bauss M Wagner LH Hothorn 2002 Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats J Rheumatol 29 990 998
15. JP Brown MR Kendler MR [tmp] McClung RD Emkey JD Adachi MA Bolognese Z Li A Balske R Lindsay 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis Calcif Tissue Int 71 103 111
16. NB Watts R Lindsay Z Li C Kasibhatla J Brown 2003 Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate Osteoporos Int 14 437 441
17. T Schnitzer HG Bone G Crepaldi S Adami M [tmp] McClung 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Aging Clin Exp Res 12 1 12
18. R Rizzoli SL Greenspan HG Bone III TJ Schnitzer NB Watts S Adami AJ Foldes C Roux MA Levine B Uebelhart AC Santora II A Kaur CA Peverly JJ Orloff 2002 Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopaual osteoporosis J Bone Miner Res 17 1988 1996
19. Y Ouchi H Orimo 1989 The disease of the old age and metabolic change of calcium and magnesium (in Japanese) Jpn J Geriat 26 216 221
20. H Orimo Y Sugioka M Fukunaga Y Muto T Hotokebuchi I Gorai T Nakamura K Kushida H Tanaka T Ikai Y Oh-hashi 1998 Diagnostic criteria of primary osteoporosis J Bone Miner Metab 16 139 150
21. H Orimo Y Hayashi M Fukunaga T Sone S Fujiwara M Shiraki K Kushida S Miyamoto S Soen J Nishimura Y Oh-hashi T Hosoi I Gorai H Tanaka T Igai H Kishimoto 2001 Diagnostic criteria for primary osteoporosis: year 2000 revision J Bone Miner Metab 19 331 337
22. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Rockville, Division of Metabolic and Endocrine Drug Products Food and Drug Administration (1994)
23. D Uebelhart E Gineyts M-C Chapuy PD Delmas 1990 Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease Bone Miner 8 87 96
24. R Eastell I Barton RA Hannon A Chimes P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 1051 1056
25. SL Greenspan HN Rosen RA Parker 2000 Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women J Clin Endocrinol Metab 85 3537 3540
26. P Ganero WJ Shih E Gineyts DB Karpf PD Delmas 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment J Clin Endocrinol Metab 79 1693 1700
27. HG Bone S Adami R Rizzoli M Favus PD Ross A Santra S Praharada A Daifotis J Orloff J Yates 2000 Weekly administration of alendronate: rationale and plan for clinical assessment Clin Ther 22 15 28